Quest diagnostics launches new 88-compound novel psychoactive substance test panel

Xylazine found in 1 in 12 specimens tested, finds new 'drug misuse in america' health trends® report on the rising polysubstance crisis secaucus, n.j. , dec. 19, 2023 /prnewswire/ -- quest diagnostics (nyse: dgx), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (nps).
DGX Ratings Summary
DGX Quant Ranking